[go: up one dir, main page]

PE20010744A1 - USE OF (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENYL) -3,5-DIMETHYL-2-MORPHOLINOL FOR THE TREATMENT OF OBESITY - Google Patents

USE OF (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENYL) -3,5-DIMETHYL-2-MORPHOLINOL FOR THE TREATMENT OF OBESITY

Info

Publication number
PE20010744A1
PE20010744A1 PE2000001089A PE0010892000A PE20010744A1 PE 20010744 A1 PE20010744 A1 PE 20010744A1 PE 2000001089 A PE2000001089 A PE 2000001089A PE 0010892000 A PE0010892000 A PE 0010892000A PE 20010744 A1 PE20010744 A1 PE 20010744A1
Authority
PE
Peru
Prior art keywords
morpholinol
dimethyl
obesity
difluorophenyl
treatment
Prior art date
Application number
PE2000001089A
Other languages
Spanish (es)
Inventor
David Lee Musso
Jessica E Matthews
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9924275.2A external-priority patent/GB9924275D0/en
Priority claimed from GB0001861A external-priority patent/GB0001861D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20010744A1 publication Critical patent/PE20010744A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE AL USO DE (2S,3S,5R)-2-(3,5-DIFLUOROFENIL)-3,5-DIMETIL-2-MORFOLINOL DE FORMULA I, PARA TRATAR LA OBESIDAD, SUPRIMIR EL APETITO, CAUSAR LA PERDIDA DE PESO, PREVENIR EL AUMENTO DE PESOREFERS TO THE USE OF (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENIL) -3,5-DIMETHYL-2-MORPHOLINOL OF FORMULA I, TO TREAT OBESITY, TO SUPPRESS APPETITE, TO CAUSE WEIGHT LOSS , PREVENT WEIGHT GAIN

PE2000001089A 1999-10-13 2000-10-11 USE OF (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENYL) -3,5-DIMETHYL-2-MORPHOLINOL FOR THE TREATMENT OF OBESITY PE20010744A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9924275.2A GB9924275D0 (en) 1999-10-13 1999-10-13 Method for the treatment of obesity
GB0001861A GB0001861D0 (en) 2000-01-28 2000-01-28 Method for the treatment of obesity

Publications (1)

Publication Number Publication Date
PE20010744A1 true PE20010744A1 (en) 2001-07-23

Family

ID=26243494

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001089A PE20010744A1 (en) 1999-10-13 2000-10-11 USE OF (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENYL) -3,5-DIMETHYL-2-MORPHOLINOL FOR THE TREATMENT OF OBESITY

Country Status (6)

Country Link
EP (1) EP1220673A2 (en)
JP (1) JP2003511410A (en)
AR (1) AR026022A1 (en)
AU (1) AU7750100A (en)
PE (1) PE20010744A1 (en)
WO (1) WO2001026641A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04001165A (en) 2001-08-08 2004-05-20 R Orton Kevin Apparatus and method for electrically conductive weight reduction.
KR20110043664A (en) * 2002-05-17 2011-04-27 듀크 유니버시티 Obesity Treatment
CA2522708C (en) 2003-04-29 2013-05-28 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
ES2761812T3 (en) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composition and methods of increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
US20090203695A1 (en) * 2007-12-05 2009-08-13 Biovitrum Ab Compounds IV
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
MX2010013353A (en) * 2008-06-04 2010-12-21 Astrazeneca Ab New compounds vii.
EP2523557B1 (en) 2010-01-11 2019-09-25 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
PT2858640T (en) 2012-06-06 2020-06-30 Nalpropion Pharmaceuticals Llc Methods of treating overweight and obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8924528D0 (en) * 1989-10-31 1989-12-20 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
JP2001524960A (en) * 1997-04-24 2001-12-04 メルク シヤープ エンド ドーム リミテツド Use of an NK-1 receptor antagonist to treat an eating disorder
WO1999025355A1 (en) * 1997-11-14 1999-05-27 Glaxo Group Ltd. Method of treating addiction to nicotine products
AP1229A (en) * 1998-01-21 2003-12-04 Glaxo Group Ltd Pharmaceutically active morpholinol.
MA26693A1 (en) * 1998-09-28 2004-12-20 Glaxo Group Ltd COMPOSITIONS FOR ORAL ADMINISTRATION

Also Published As

Publication number Publication date
WO2001026641A3 (en) 2002-01-10
AU7750100A (en) 2001-04-23
WO2001026641A2 (en) 2001-04-19
EP1220673A2 (en) 2002-07-10
JP2003511410A (en) 2003-03-25
AR026022A1 (en) 2002-12-26

Similar Documents

Publication Publication Date Title
NO20003233L (en) 4-hydroxyquinoline-3-carboxamides and hydrazides as antivirals
CY1111050T1 (en) PHOSPHONES, MONO-PHOSPHONAMIDES, BISPHOSPHONAMIDES FOR THE TREATMENT OF VIRUS DISEASES
ATE384058T1 (en) THIAZOLE DERIVATIVES
DE69830504D1 (en) ANTITROMOMBOTIC MEANS
MA27040A1 (en) SUBSTITUTED NUCLEOSIDES IN 4 '
NO20044995L (en) Heterocyclic compounds
BRPI0417684A (en) compound, pharmaceutical composition, and use of a compound
CY1111693T1 (en) ANTIQUE FACTORS
GEP20074197B (en) 5ht2c receptor modulators
BR0109703A (en) Piperazine Derivatives
PT1200412E (en) IMIDAZOLE ANTI-PROLIFERATIVE AGENTS
DE602004012858D1 (en) 2-AMINOBENZOTHIAZOLE AS CB1 RECEPTOR INVERSE AGONISTS
HRP20050516B1 (en) N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobials
ATE484508T1 (en) FURYL COMPOUNDS
DE60333746D1 (en) thienyl compounds
MXPA05007115A (en) Novel cb 1 receptor inverse agonists.
PE20010744A1 (en) USE OF (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENYL) -3,5-DIMETHYL-2-MORPHOLINOL FOR THE TREATMENT OF OBESITY
EP1643984A4 (en) Use of parthenolide derivatives as antileukemic and cytotoxic agents
PE20010541A1 (en) USE OF A BENZIMIDAZOLE COMPOSITION TO TREAT CANCER
AR032432A1 (en) ONCOLITICAL COMBINATIONS FOR CANCER TREATMENT
MY129310A (en) C-4 carbonate taxanes
BR0205812A (en) Benzimidazoles Useful in the Treatment of Sexual Dysfunction
SE9901077D0 (en) Novel use
BR0311491A (en) Compound, Pharmaceutical Composition, Use of a Compound, and, Therapeutic Method to Treat Cancer in a Mammal
DE60001850D1 (en) CHALCON COUMARINE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal